PMID: 8472722Apr 1, 1993Paper

Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure

European Heart Journal
F Hagemeijer

Abstract

Calcium sensitization increases myocardial contractility by improving energy utilization of the myocardium, without an increase in intracellular concentrations of cyclic adenosine monophosphate. The calcium sensitizer most extensively studied up to now is pimobendan (UD-CG 115 BS). Vasodilatation results primarily from phosphodiesterase III inhibition. Orally administered pimobendan appears rapidly in plasma. A peak concentration is reached 1.5 h after drug intake; elimination from the plasma compartment has a half-life of 1.5 h. First-pass hepatic O-desmethylation of pimobendan produces the active metabolite UD-CG 212; plasma concentration curves of UD-CG 212 are similar to those of pimobendan, with a peak concentration 1-2 h later than the peak concentration of the parent compound. In patients with chronic congestive heart failure, pimobendan produces a dose-dependent and prolonged decrease in pulmonary capillary wedge pressure and an increase in cardiac output. Maintenance doses of pimobendan are well tolerated and may lead to lasting symptomatic improvement in patients with heart failure; open and blinded trials show that exercise tolerance increases. No attenuation of these effects is seen during long-term therapy with pim...Continue Reading

Citations

Nov 1, 1995·Clinical and Experimental Pharmacology & Physiology·L Brown
Jul 25, 2013·American Journal of Veterinary Research·Marisa K AmesStephen R Werre
Jan 1, 1997·Cardiovascular Drugs and Therapy·P A van Zwieten
Jul 11, 2006·Journal of the American Animal Hospital Association·Christophe W LombardClaudio M Bussadori
May 2, 2003·Expert Opinion on Investigational Drugs·Masao Endoh
Aug 1, 1995·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·S A PahernikH G Koebe
Oct 4, 2005·Autonomic Neuroscience : Basic & Clinical·Michiro MaruyamaShuichi Kaneko
Sep 10, 2003·Journal of Cardiovascular Pharmacology·Tadahito NaritaSeiichiro Kawashima
Aug 29, 2002·Journal of Cardiovascular Pharmacology·Masao Endoh
May 21, 2019·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·Jonathan BrettJared Brown

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.